Specialty Pharmacy and the Evolution of Cancer Care

Apr 27, 2015

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses the changing role of specialty pharmacy in cancer treatment.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses the changing role of specialty pharmacy in cancer treatment.

This video was shot at the Armada Health Care 2014 Specialty Pharmacy Summit and Expo in Las Vegas, Nevada.

Related Videos

Credit: thodonal - stock.adobe.com

Credit: Lars Neumann - stock.adobe.com

Image Credit: Adobe Stock - peterschreiber.media

Conference attendees watching a speaker | Image credit: kasto - stock.adobe.com

Biosimilars | Image credit: lexiconimages - stock.adobe.com

Medical care team | Image credit: Iryna - stock.adobe.com

Related Content

Efficacy of Upadacitinib Maintained for 3 Years for Those With Psoriatic Arthritis

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

Key Metrics That Support the Integrated Specialty Pharmacy Model

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

April 17th 2023

Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple Myeloma

Nivolumab-AVD Poised to be New Standard of Care for Hodgkin Lymphoma in Both Adults, Pediatric Patients

Efficacy of Upadacitinib Maintained for 3 Years for Those With Psoriatic Arthritis

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

Key Metrics That Support the Integrated Specialty Pharmacy Model

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

April 17th 2023

Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple Myeloma

Nivolumab-AVD Poised to be New Standard of Care for Hodgkin Lymphoma in Both Adults, Pediatric Patients

Efficacy of Upadacitinib Maintained for 3 Years for Those With Psoriatic Arthritis

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

Key Metrics That Support the Integrated Specialty Pharmacy Model

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

April 17th 2023

Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple Myeloma

Nivolumab-AVD Poised to be New Standard of Care for Hodgkin Lymphoma in Both Adults, Pediatric Patients

Related Content

Acute psoriasis on the elbows is an autoimmune incurable dermatological skin disease. Large red, inflamed, flaky rash on the knees. Joints affected by psoriatic arthritis | Image Credit: SNAB - stock.adobe.com

Efficacy of Upadacitinib Maintained for 3 Years for Those With Psoriatic Arthritis

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

Pharmacist holding medicine box and capsule pack in pharmacy drugstore. Credit: I Viewfinder - stock.adobe.com

Key Metrics That Support the Integrated Specialty Pharmacy Model

Pharmacy Focus: Oncology Edition

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

April 17th 2023

Multiple Myeloma multiplex leukemia cancer 3d color render illustration closeup.Credit: LASZLO - stock.adobe.com.

Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple Myeloma

Hodgkin's lymphoma, light micrograph, photo under microscope. Credit: Dr_Microbe - stock.adobe.com

Nivolumab-AVD Poised to be New Standard of Care for Hodgkin Lymphoma in Both Adults, Pediatric Patients

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.